KioMedinevsone

Unique single-injection biodegradable fluid implant for knee osteoarthritis

Explore KioMedineVSone and learn why it may be the treatment of choice for your patients experiencing knee OA pain.

KioMedineVSone is a medical device under the directive 93/42/EEC (CE 0344).
Champignon

The Product

A new product class for the treatment of knee osteoarthritis

Packaging produit

KioMedineVSone is a unique biodegradable fluid implant indicated for the symptomatic treatment of knee osteoarthritis with a single intraarticular injection. KioMedineVSone is based on a world-first, exclusive, animal-free KioMedine® (CM) Carboxymethyl-Chitosan.

KioMedineVSone is the treatment of choice for refractory osteoarthritis patients.

Homeostasis restoration

How it works

Exclusive Belgian technology with unique properties

Kiomedine® CM-Chitosan is a highly purified polysaccharide derived from Agaricus Bisporus (button mushroom) resulting from years of research and innovation and is a patented technologysup>1,2>/sup> manufactured by KiOmed Pharma in Belgium.

Thanks to a unique structure that differs from natural chitosan, CM-Chitosan provides to KioMedineVSone an exclusive dual mechanism of action to tackle osteoarthritis pain and other symptoms by enhancing joint lubrication and by reducing oxidative stress (protection)3,4.

The lubrication and ROS scavenger properties of KioMedinevsone are properties potentially helping to disrupt the OA vicious cycle, and therefore providing relief of the OA-related symptoms on the long-term.

graphic pain evolution

Clinical evidence

KioMedineVSone demonstrates 73.5% pain reduction score with high responder rate up to 12 months in refractory OA patients4.

  • Rapid onset

    Rapid onset on pain relief (1 to 2 weeks)5,6,7.

  • Long-lasting relief

    relief on OA symptoms (pain, stiffness, physical function) on difficult to treat patients (PF, obese and TKR indicated)7.

  • High response rate

    (>90%) at 12 months7.

  • 90% physician and patient satisfaction at 12 months7.

Hear from peers

  • The Button Mushroom: A Genuine Innovation in Osteoarthritis - SFR 2024 Round Table

    Relive the multidisciplinary round table organized by KiOmed Pharma during the 2024 Congress of the French Society of Rheumatology (SFR). This session, moderated by Prof. Xavier Chevalier and a panel of seven experts, explores the potential of carboxymethyl-chitosan (CMC), derived from the Paris mushroom, as an innovative therapeutic solution for refractory osteoarthritis.

  • What is the role of carboxymethyl chitosan?

    Dr. Philippe Van Overschelde presents a new generation fluid implant for the symptomatic treatment of knee osteoarthritis based on world-first exclusive animal-free carboxymethyl chitosan (KiOmedine® CM-chitosan). He explains the exclusive dual mechanism of action to tackle osteoarthritis discomfort and other symptoms by reducing oxidative stress and enhancing joint lubrication.

  • What is the clinical experience of this new fluid implant?

    What are the clinical benefits of this new fluid implant KioMedineVSone? In addition to in vitro and in vivo tests, the APROOVE clinical study was conducted and demonstrated the safety and effectiveness of KioMedineVSone in reducing symptoms after a single injection in OA patients. Dr Philippe Van Overschelde explains the latest results in a real-life trial for refractory OA patients.

  • Clinical routine before or after single injection

    Dr. Philippe Van Overschelde presents the medical assessment before and after injecting the fluid implant KioMedine-vs-one.

Want to find out more?

To receive more informations on KioMedineVSone and receive the latest informations on a new clinical data:

Discover our team and partners